← Back to Search

Crosslinking Agent

Standard vs. Accelerated Corneal Crosslinking for Keratoconus

Phase 2 & 3
Led By Francis W Price, Jr., MD
Research Sponsored by Price Vision Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented keratoconus or ectasia after refractive surgery
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will compare two methods of corneal crosslinking, accelerated and standard, to see which is more effective in treating progressive keratoconus or corneal ectasia.

Who is the study for?
This trial is for people with progressive keratoconus or corneal ectasia after refractive surgery. It's not suitable for those with conditions affecting eye healing, a history of chemical injury or slow healing, known sensitivity to the medications used in the study, pregnant individuals, those with thin corneas, or other ocular conditions that could complicate treatment.Check my eligibility
What is being tested?
The trial aims to compare two methods of corneal crosslinking: accelerated and standard. Both use riboflavin (vitamin B2) drops but differ in how quickly UV light is applied to strengthen the cornea and halt progression of keratoconus or ectasia.See study design
What are the potential side effects?
Potential side effects may include discomfort during treatment, temporary vision changes like haziness, risk of infection due to eye surface disruption during procedure, and delayed recovery leading to prolonged blurry vision.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have been diagnosed with keratoconus or had corneal thinning after eye surgery.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in maximum keratometry
Secondary outcome measures
Change in corrected distance visual acuity
Change in uncorrected distance visual acuity

Trial Design

2Treatment groups
Active Control
Group I: AcceleratedActive Control1 Intervention
Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
Group II: StandardActive Control1 Intervention
Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes

Find a Location

Who is running the clinical trial?

Price Vision GroupLead Sponsor
11 Previous Clinical Trials
1,173 Total Patients Enrolled
1 Trials studying Keratoconus
510 Patients Enrolled for Keratoconus
Francis W Price, Jr., MDPrincipal InvestigatorPrice Vision Group
5 Previous Clinical Trials
2,938 Total Patients Enrolled

Media Library

Riboflavin 0.1% (Crosslinking Agent) Clinical Trial Eligibility Overview. Trial Name: NCT03922542 — Phase 2 & 3
Keratoconus Research Study Groups: Accelerated, Standard
Keratoconus Clinical Trial 2023: Riboflavin 0.1% Highlights & Side Effects. Trial Name: NCT03922542 — Phase 2 & 3
Riboflavin 0.1% (Crosslinking Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03922542 — Phase 2 & 3
Keratoconus Patient Testimony for trial: Trial Name: NCT03922542 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we able to sign up for this experiment yet?

"That is correct, the clinical trial mentioned is looking for more participants and was last updated on 7/27/2022. The study requires 510 patients in total from 1 location."

Answered by AI

What types of medical conditions does Accelerated treatment usually address?

"dietary and nutritional therapies are often accelerated. This treatment is also effective for other conditions such as vitamin deficiency, joint pain, and supplementing vitamins."

Answered by AI

Is the Accelerated program unique or have other organizations done something similar?

"Right now, 20 different research trials are investigating Accelerated. Out of those 20, 11 are in the third stage. Most of the investigations for Accelerated take place in San Francisco; however, studies related to this topic are spread out over 47 locations."

Answered by AI

Who else is applying?

What state do they live in?
What site did they apply to?
Price Vision Group
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

I have progressive Keratoconus and received corneal cross linking in my left eye. Upon further testing I have been referred to treat my right eye. Expense is a concern. I want to help others with my condition to prevent further issues and prevent a corneal transplant in my future.
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Phone Call
Most responsive sites:
  1. Price Vision Group: < 48 hours
Recent research and studies
~140 spots leftby May 2026